丽珠医药(01513)子公司获批国内首个完带汤颗粒 进一步完善3.1类中药布局

公告速递
Oct 27

丽珠医药(01513)10月27日发布自愿公告称,其子公司四川光大制药有限公司已收到国家药品监督管理局签发的《药品注册证书》,产品为完带汤颗粒,注册分类为中药3.1类,证书编号为2026S03950,药品批准文号为“国药准字C20260024”,有效期至2031年10月25日。

本次获批的完带汤颗粒为国内首家上市,同样是公司获批的第二款3.1类新药,剂型为颗粒剂,单袋规格相当于饮片22.13g。处方源自《傅青主女科》收录的经典名方“完带汤”,主治肝郁脾虚、湿浊下注所致带下病等妇科疾病。

截至公告披露日,完带汤颗粒累计直接投入研发费用约人民币447.46万元。公司表示,鉴于该产品刚获注册批件,预计短期内对经营业绩不会产生重大影响,但将丰富公司产品管线,并提升市场竞争力。

丽珠医药提醒投资者,药品销售受国家政策与市场环境等因素影响,具有不确定性,请投资者注意风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10